Sirisha L. Mushti

Sirisha L. Mushti

Auto-generated profile, based on publicly available information

Sirisha L. Mushti

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. 1

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SMSirisha L. Mushti
Sirisha L. Mushti
FMFlora Mulkey
Flora Mulkey
RSRajeshwari Sridhara
Rajeshwari Sridhara
Purpose: With the approval of immunotherapies for a variety of indications, methods to assess treatment benefit addressing the response patterns observed are important. We evaluated RECIST criteria–based overall response rate (ORR) and progression-free survival (PFS) as potential surrogate endpoints of overall survival (OS), and explored a modified definition of PFS by altering the threshold percentage determining disease progression to assess the association with survival benefit in immunotherapy trials. Experimental Design: Thirteen randomized, multicenter, active-control trials containing immunotherapeutic agents submitted to the FDA were analyzed. Associations between treatment effects of ORR, PFS, modified PFS, and OS were evaluated at individual and trial levels. Patient-level responder analysis was performed for PFS and OS. Results: The coefficient of determination (R²) measured the strength of associations, where values near 1 imply surrogacy and values close to 0 suggest no association. At the trial level, the association between hazard ratios (HR) of PFS and OS was R2 = 0.1303, and between the odds ratio (OR) of ORR and HR of OS was R2 = 0.1277. At the individual level, the Spearman rank correlation coefficient between PFS and OS was 0.61. Trial-level associations between modified PFS and OS ranged between 0.07 and 0.1, and individual-level correlations were approximately 0.6. HRs of PFS and OS for responders versus nonresponders were 0.129 [95% confidence interval (CI), 0.11–0.15] and 0.118 (95% CI, 0.11–0.13), respectively. Conclusions: Although responders exhibited longer survival and PFS than nonresponders, the trial-level and individual-level associations were weak between PFS/ORR and OS. Modifications to PFS did not improve associations. Clin Cancer Res; 24(10); 2268–75. ©2018 AACR. See related commentary by Korn and Freidlin, p. 2239

29 May 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
MFMichael J. Fusco
Michael J. Fusco
SCSandra J. Casak
Sandra J. Casak
SMSirisha L. Mushti
Sirisha L. Mushti
JCJoyce Cheng
Joyce Cheng
BCBrian J. Christmas
Brian J. Christmas
SLSteven J. Lemery
Steven J. Lemery
On November 8, 2023, the FDA approved fruquintinib, an inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type and medically appropriate, an anti-EGFR therapy. Approval was based on Study FRESCO-2, a globally conducted, double-blind, placebo-controlled randomized trial. The primary endpoint was overall survival (OS). The key secondary endpoint was progression-free survival. A total of 691 patients were randomly assigned (461 and 230 into the fruquintinib and placebo arms, respectively). Fruquintinib provided a statistically significant improvement in OS with a hazard ratio (HR) of 0.66 [95% confidence interval (CI), 0.55, 0.80; P < 0.001]. The median OS was 7.4 months (95% CI, 6.7, 8.2) in the fruquintinib arm and 4.8 months (95% CI, 4.0, 5.8) for the placebo arm. Adverse events observed were generally consistent with the known safety profile associated with the inhibition of VEGFR. The results of FRESCO-2 were supported by the FRESCO study, a double-blind, single-country, placebo-controlled, randomized trial in patients with refractory mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. In FRESCO, the OS HR was 0.65 (95% CI, 0.51, 0.83; P < 0.001). FDA concluded that the totality of the evidence from FRESCO-2 and FRESCO supported an indication for patients with mCRC with prior treatment with fluoropyrimidine, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type and medically appropriate, an anti-EGFR therapy.

8 June 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SGShruti U. Gandhy
Shruti U. Gandhy
SCSandra J. Casak
Sandra J. Casak
SMSirisha L. Mushti
Sirisha L. Mushti
JCJoyce Cheng
Joyce Cheng
SSSriram Subramaniam
Sriram Subramaniam
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
On September 30, 2022, the FDA granted accelerated approval to futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions or other rearrangements. Approval was based on Study TAS-120–101, a multicenter open-label, single-arm trial. Patients received futibatinib 20-mg orally once daily. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DoR) as determined by an independent review committee (IRC) according to RECIST v1.1. ORR was 42% (95% confidence interval, 32%–52%). Median DoR was 9.7 months. Adverse reactions occurring in ≥30% patients were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, and abdominal pain. The most common laboratory abnormalities (≥50%) were increased phosphate, increased creatinine, decreased hemoglobin, and increased glucose. Ocular toxicity (including dry eye, keratitis, and retinal epithelial detachment) and hyperphosphatemia are important risks of futibatinib, which are listed under Warnings and Precautions. This article summarizes the FDA's thought process and data supporting the approval of futibatinib.

27 August 2020 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
SMSirisha L. Mushti
Sirisha L. Mushti
FMFlora Mulkey
Flora Mulkey
STShenghui Tang
Shenghui Tang
HSHarpreet Singh
Harpreet Singh
SLSteven J. Lemery
Steven J. Lemery
JBJulia A. Beaver
Julia A. Beaver

9 December 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
VKVaibhav Kumar
Vaibhav Kumar
LDLeslie Doros
Leslie Doros
MTMargaret Thompson
Margaret Thompson
SMSirisha L. Mushti
Sirisha L. Mushti
RCRosane Charlab
Rosane Charlab
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
On May 15, 2020, the FDA approved ripretinib for adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with three or more kinase inhibitors, including imatinib. The approval was based on results from INVICTUS (NCT03353753), an international, multi-center, double-blind, placebo-controlled trial. Patients were randomly allocated (2:1) to receive either ripretinib 150 mg once daily (n = 85) or matching placebo (n = 44). The trial demonstrated a statistically significant improvement in progression-free survival (PFS) as assessed by modified RECIST v1.1 by blinded independent central review for patients randomized to ripretinib, with a median PFS of 6.3 months [95% confidence interval (CI): 4.6–6.9] compared with 1.0 month (95% CI: 0.9–1.7) for placebo [HR: 0.15 (95% CI: 0.09–0.25); P < 0.0001, stratified log-rank test]. There was no statistically significant difference in objective response rate in the ripretinib arm, 9% (95% CI: 4.2–18) compared with placebo 0% [(95% CI: 0–8); P = 0.0504, Fisher exact test]. The median overall survival (OS) in the ripretinib arm was 15.1 months (95% CI: 12.3–15.1) compared with 6.6 months (95% CI: 4.1–11.6) in the placebo arm. A formal statistical comparison of OS was not made due to the prespecified hierarchical analysis plan. The most common (≥20%) adverse events with ripretinib, in order of decreasing frequency, were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia, and vomiting. Other important risks of ripretinib include new primary cutaneous malignancies, hypertension, and cardiac dysfunction.

1 April 2023
Verified
Other
Open access
VKVaibhav Kumar
Vaibhav Kumar
LDLeslie Doros
Leslie Doros
MTMargaret Thompson
Margaret Thompson
SMSirisha L. Mushti
Sirisha L. Mushti
RCRosane Charlab
Rosane Charlab
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
FDA Benefit Risk Assessment and Summary